Quick Search 
Journals Home
Drugs of Today
on the Web
Drugs of Today
Information
Subscription Order Form
Reprints &
Permissions
My
Profile
Contact
Us
Shopping
Cart
Purchase
History
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2019, 55(7): 459
ISSN 1699-3993
Copyright 2019 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2019.55.7.3015642		 
 
Talazoparib to treat BRCA-positive breast cancer
Guney Eskiler, G.		 
 
Talazoparib tosylate (BMN-673, Talzenna; Pfizer) is an oral poly [ADP-ribose] polymerase (PARP) inhibitor (PARPi) that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of germline BRCA-mutated locally advanced or metastatic breast cancer (BC). In preclinical and clinical studies, talazoparib exerted superior efficacy and offered a significant clinical benefit in advanced or metastatic BC patients harboring germline BRCA mutations compared with other PARPi and standard chemotherapy regimens through the concept of synthetic lethality. Thus, this review provides insight into the results of preclinical and clinical studies, highlights the current challenges of talazoparib and suggests innovative approaches to further improve its clinical efficacy and expand the use of talazoparib in advanced BC and/or triple-negative BC treatments beyond BRCA mutations.


Full Text: PDF 		 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy